Becton, Dickinson and Company (NYSE:BDX) Stock Gets Downgrade from Zacks Research

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Citigroup upped their price objective on Becton, Dickinson and Company from $208.00 to $241.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the stock a “sector perform” rating in a report on Friday, November 6th. JPMorgan Chase & Co. boosted their target price on shares of Becton, Dickinson and Company from $170.00 to $202.00 and gave the stock a “neutral” rating in a report on Friday, November 6th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $197.47.

Check Out Our Latest Research Report on Becton, Dickinson and Company

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $212.19 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The stock’s 50-day simple moving average is $194.40 and its 200 day simple moving average is $170.85. The company has a market cap of $58.47 billion, a P/E ratio of 51.25, a P/E/G ratio of 3.63 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $140.11 and a 52-week high of $220.36.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.08. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.96 earnings per share. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 5th that authorizes the company to buy back 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Share repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $23,134,230. This represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 3,310 shares of company stock valued at $688,650. 0.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. Bank of America Corp DE acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at about $474,993,000. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Becton, Dickinson and Company during the second quarter worth about $247,372,000. Finally, Deutsche Bank AG bought a new position in Becton, Dickinson and Company during the second quarter worth about $204,226,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Recommended Stories

Analyst Recommendations for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.